Alpha Tau Medical to Participate in Key Investor Conferences
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW), a leader in innovative alpha-radiation cancer therapy, is preparing to participate in several significant investor conferences. This involvement underscores the company's dedication to sharing advancements in cancer treatment technology, particularly its proprietary method known as Alpha DaRT.
Upcoming Conference Presentations
At these conferences, Alpha Tau's CFO, Raphi Levy, will present a corporate overview and share updates on the latest developments concerning the Alpha DaRT therapy. These presentations offer valuable opportunities for investors and stakeholders to gain insight into Alpha Tau's progress in oncology and medical innovation.
H.C. Wainwright 26th Annual Global Investment Conference
Alpha Tau Medical will be presenting at the H.C. Wainwright Annual Global Investment Conference on September 10th. During this session, Raphi Levy will discuss the company's strategic direction and upcoming initiatives. Attendees are encouraged to join this informative presentation.
Sidoti Small-Cap Virtual Investor Conference
Following that, the company will also take part in the Sidoti Small-Cap Virtual Investor Conference on September 18-19. This event is designed to promote dialogue between small-cap companies and potential investors, with Levy providing an update that highlights the unique features of Alpha Tau’s technology.
Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference
Alpha Tau Medical will participate in the Redburn Atlantic and Rothschild & Co 2024 Radiopharma Conference on September 26th. This specialized conference provides an opportunity for the company to connect with investors who are specifically interested in pharmacological and therapeutic advancements driven by cutting-edge research.
Lytham Partners Fall 2024 Investor Conference
To conclude this series of presentations, Alpha Tau will appear at the Lytham Partners Fall 2024 Investor Conference on October 1st. This event will further facilitate engagement and showcase the company's ongoing advancements in cancer therapies.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an oncology therapeutics company based in Israel, focused on the research, development, and commercialization of its innovative cancer treatment technology, Alpha DaRT. This groundbreaking method specifically targets solid tumors, utilizing alpha radiation to enhance therapeutic effects while aiming to minimize damage to surrounding healthy tissue.
About Alpha DaRT
Alpha DaRT, which stands for Diffusing Alpha-emitters Radiation Therapy, utilizes intratumoral delivery of radium-224 to achieve precise and effective alpha-irradiation. As the radium decays, it emits short-lived daughter isotopes that release high-energy alpha particles capable of destroying tumor cells. Designed specifically for solid tumors, Alpha DaRT offers a targeted treatment approach that seeks to protect adjacent healthy tissues.
Investor Relations Contact
If you have any inquiries, please contact the investor relations team via email at IR@alphatau.com.
Frequently Asked Questions
What is Alpha DaRT therapy?
Alpha DaRT is an innovative cancer treatment that employs alpha radiation to specifically target and eliminate solid tumors while minimizing harm to surrounding healthy tissue.
Who will present for Alpha Tau at the conferences?
CFO Raphi Levy will represent Alpha Tau Medical at all of the upcoming investor conferences.
When is the H.C. Wainwright Conference?
The H.C. Wainwright 26th Annual Global Investment Conference is set for September 10th.
How can investors learn more about Alpha Tau's progress?
Investors can attend the company's presentations at the scheduled conferences or reach out to the investor relations team for more detailed information.
What is the significance of the conferences for Alpha Tau?
These conferences present a crucial opportunity for Alpha Tau Medical to engage with investors, showcase its advancements, and discuss strategic initiatives related to its treatments.
